Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes.

ABSTRACT:

Aims/introduction

Chemerin, a novel member of the family of adipocytokines, has been shown to be associated with insulin resistance, as well as micro- and macrovascular complications of diabetes. We investigated the effects of pioglitazone and metformin, two commonly prescribed antidiabetic agents, on the reduction of serum chemerin concentrations.

Materials and methods

In an open-labeled randomized clinical trial, 81 patients with newly diagnosed type 2 diabetes who were not taking antidiabetic medications were recruited. Patients were randomly assigned to either pioglitazone 30 mg daily or metformin 1,000 mg daily. Serum chemerin concentrations, indices of glycemic control, serum lipids concentrations, and anthropometric parameters were measured at baseline and after 3 mon

SUBMITTER: Esteghamati A 

PROVIDER: S-EPMC4020338 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature